PARIS--(BUSINESS WIRE)--PathoQuest, a rapidly growing biotechnology company spun out from Institut Pasteur, today announced the expansion of its Executives Leadership Team with the addition of three experienced managers who have significant expertise in the fields of infectious diseases, viral safety testing and molecular diagnostics.
Helene Peyro-Saint-Paul, M.D., M.B.A., Chief Medical Officer, Pascale Beurdeley, Ph.D., Chief Scientific Officer, and Jean-Marie Charpin, Ph.D., Global Commercial Head, Viral Safety join PathoQuest’s Executive Management Team to help lead the next phase of growth for the company.
As CMO, Dr. Peyro-Saint-Paul will be in charge of Medical Affairs, development strategy and Market Access. Helene Peyro-Saint-Paul has more than 20 years of experience in the healthcare industry. In the first part of her career, as International Medical Director at Serono and Global Strategic Marketing Director at Actelion, she was responsible for the international development and European and US launch of several innovative drugs in neurology or orphan diseases. She then moved to the in vitro diagnostic industry. At QIAGEN Marseille (formerly Ipsogen) and HalioDx (that she cofounded), she served as Chief Medical Officer and developed her expertise in the management of start-ups and medical validation and market access of innovative diagnostic tests, more specifically in oncology and NGS. Dr. Peyro-Saint-Paul trained as a neurologist in Toulouse (France) and received an Executive MBA from ESSEC Business School (Paris, France).
As CSO, Dr. Beurdeley will lead PathoQuest’s research and development activities while providing insight and expertise on all the scientific aspects of the company’s technology. Prior to joining PathoQuest, Dr. Beurdeley held several positions at DiaxonHit (formerly ExonHit Therapeutics) where she contributed to the development and the promotion of the company’s proprietary platform for the analysis of gene expression and alternative splicing. She was also in charge of the implementation and the management of innovative R&D projects in oncology and Alzheimer’s disease. In addition, she developed her expertise in the conception and development of innovative diagnostic products in compliance with regulatory requirements. Prior to joining ExonHit Therapeutics, Dr. Beurdeley held a researcher position in the translational medicine department at the Curie Institute. Dr. Beurdeley is graduated from the University Louis Pasteur (Strasbourg, France) and holds a Ph.D. in Molecular and Cell Biology. She completed her training as a post-doctoral fellow at Magainin Pharmaceuticals Inc (PA, USA).
As Commercial Head of Viral Safety, Dr. Charpin will drive commercial efforts associated with PathoQuest’s Viral Safety Testing business. Prior to joining PathoQuest, Dr. Charpin was Business Account Manager and Product Manager at OncoDesign. He developed the business in north Europe and successfully launch innovative services for preclinical Oncology worldwide. Prior to this, he was leading the sales team in France for SGS GMP Laboratory services in analytical chemistry and microbiology. As Sales Manager at Texcell, he developed the biosafety and Immunology business through North Europe and coordinated the Indian Distributor. Since joining the CRO business, he developed his knowledge of the regulatory requirements (particularly in viral safety, QC testing and preclinical development) and showed a customer oriented mindset. Mr. Charpin holds a PhD in Medical Biology with a focus on quantitative PCR applied to Immunology from Faculty of Medicine Necker-Enfants Malades, University of Paris Descartes.
“This is an exciting period of growth for PathoQuest and I am very pleased to welcome these new members to our Executive Leadership Team,” stated Jean-Francois Brepson, PathoQuest’s CEO. “Each of them will play a critical role as we accelerate the development and commercialization of our NGS-based testing solutions. I would also like to thank PathoQuest’s founder, Prof. Marc Eloit, for his major contribution to building the company and positioning it very competitively for the future. Moving forward, Marc will be transitioning to a scientific advisory role.”
Greater Pathogen Detection for Better Decisions
PathoQuest, a spin out of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improve pathogen detection in biological samples. PathoQuest’s technology, which combines NGS, a proprietary sample preparation process, applicable to several types of samples, a comprehensive and curated database of pathogens genomic sequence information and an automated analysis pipeline, provides clinicians and biopharma companies with a comprehensive analysis covering all known relevant human pathogens and bioproduction viral contaminants. This method overcomes the current limitation of pathogens detection, i.e. the need to specify the pathogens to be analyzed. PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first revenue-generating commercial application of its NGS testing approach, and is used by several major biopharma companies.
To learn more about PathoQuest, visit www.pathoquest.com.